Bayer AG Euro
50.02
(-0.18 %)

Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

q1 2021 button 190x107

Quarterly Statement First Quarter 2021
DOWNLOAD TOOL
Investment Case
Event Highlights
August 5, 2021
Investor Conference Call

Q2 2021 Results

READ MORE
July 29, 2021
Investor Conference Call

Bayer announces update on five-point plan

read more
May 12, 2021
Investor Conference Call

Q1 2021 Results

read more
VIEW ALL EVENTS
News from Bayer
August 03, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
READ MORE
July 29, 2021
Bayer Provides Update on Path to Closure of Roundup™ Litigation
READ MORE
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
READ MORE
NEWS OVERVIEW
Sustainability & Governance

Our Commitment to Sustainability

LEARN MORE
Discover More Investor Resources
DIVIDENDS
Returning Value to Shareowners
LEARN MORE
DEBT
Detailed Insight into Debt & Fixed Income
LEARN MORE
Stock Charts
Discover Our Interactive Stock Charts
LEARN MORE
CORPORATE GOVERNANCE
Managing and Supervising an Enterprise
LEARN MORE
CONTACT IR TEAM
Get In Touch With Us
LEARN MORE
Newsletter
Subscribe To Our Latest Investor News
LEARN MORE
USES AND SAFETY RECORD
Let’s Talk About Glyphosate
LEARN MORE
Learn About The Litigation
Glyphosate Litigation Facts
LEARN MORE